VANDA PHARMACEUTICALS INC. Increase (Decrease) in Accrued Liabilities
VANDA PHARMACEUTICALS INC. (VNDA) reported Increase (Decrease) in Accrued Liabilities of $24.39 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-05-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2015-05-07
- VANDA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for the quarter ending 2015-03-31 was $24.39M, a 207.37% increase year-over-year.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for the quarter ending 2014-12-31 was -$323.00K, a 159.59% decline year-over-year.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for the quarter ending 2014-09-30 was $72.00K, a 90.55% decline year-over-year.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for the quarter ending 2014-06-30 was -$6.36M.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for fiscal 2014 was $1.32M.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for fiscal 2013 was -$113.00K, a 106.26% decline from fiscal 2012.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for fiscal 2012 was $1.81M, a 1.63% decline from fiscal 2011.
- VANDA PHARMACEUTICALS INC. increase (decrease) in accrued liabilities for fiscal 2011 was $1.84M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2015-03-31 | $24.39M 10-Q · filed 2015-05-07 | $24.06M derived: sum of 2 quarters · filed 2015-05-07 | $24.14M derived: sum of 3 quarters · filed 2015-05-07 | $17.77M derived: sum of 4 quarters · filed 2015-05-07 | |
| 2014-12-31 | -$323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | -$251.00K derived: sum of 2 quarters · filed 2015-03-13 | -$6.61M derived: sum of 3 quarters · filed 2015-03-13 | $1.32M 10-K · filed 2015-03-13 | |
| 2014-09-30 | $72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-27 | -$6.29M derived: sum of 2 quarters · filed 2014-10-27 | $1.65M 10-Q · filed 2014-10-27 | $2.19M derived: sum of 4 quarters · filed 2015-05-07 | |
| 2014-06-30 | -$6.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $1.57M 10-Q · filed 2014-08-08 | $2.12M derived: sum of 3 quarters · filed 2015-05-07 | $2.88M derived: sum of 4 quarters · filed 2015-05-07 | |
| 2014-03-31 | $7.93M 10-Q · filed 2015-05-07 | $7.98M 10-Q · filed 2014-05-08 | $8.48M derived: sum of 2 quarters · filed 2015-05-07 | $9.24M derived: sum of 3 quarters · filed 2015-05-07 | $9.13M derived: sum of 4 quarters · filed 2015-05-07 |
| 2013-12-31 | $542.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $1.30M derived: sum of 2 quarters · filed 2015-03-13 | $1.20M derived: sum of 3 quarters · filed 2015-03-13 | -$113.00K 10-K · filed 2015-03-13 | |
| 2013-09-30 | $762.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-27 | $658.00K derived: sum of 2 quarters · filed 2014-10-27 | -$655.00K 10-Q · filed 2014-10-27 | -$2.22M derived: sum of 4 quarters · filed 2015-03-13 | |
| 2013-06-30 | -$104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | -$1.42M 10-Q · filed 2014-08-08 | -$2.98M derived: sum of 3 quarters · filed 2015-03-13 | -$2.14M derived: sum of 4 quarters · filed 2015-03-13 | |
| 2013-03-31 | -$1.31M 10-Q · filed 2014-05-08 | -$2.88M derived: sum of 2 quarters · filed 2015-03-13 | -$2.03M derived: sum of 3 quarters · filed 2015-03-13 | -$1.50M derived: sum of 4 quarters · filed 2015-03-13 | |
| 2012-12-31 | -$1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | -$721.00K derived: sum of 2 quarters · filed 2015-03-13 | -$184.00K derived: sum of 3 quarters · filed 2015-03-13 | $1.81M 10-K · filed 2015-03-13 | |
| 2012-09-30 | $845.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $1.38M derived: sum of 2 quarters · filed 2013-11-08 | $3.37M 10-Q · filed 2013-11-08 | $3.12M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-06-30 | $537.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | $2.53M 10-Q · filed 2013-07-31 | $2.28M derived: sum of 3 quarters · filed 2014-02-25 | $3.17M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-03-31 | $1.99M 10-Q · filed 2013-05-10 | $1.71M 10-Q · filed 2012-05-09 | $1.74M derived: sum of 2 quarters · filed 2014-02-25 | $2.64M derived: sum of 3 quarters · filed 2014-02-25 | $3.01M derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | -$250.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $647.00K derived: sum of 2 quarters · filed 2014-02-25 | $1.02M derived: sum of 3 quarters · filed 2014-02-25 | $1.84M 10-K · filed 2014-02-25 | |
| 2011-09-30 | $897.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $1.27M derived: sum of 2 quarters · filed 2012-11-08 | $2.09M 10-Q · filed 2012-11-08 | $1.63M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-06-30 | $372.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $1.19M 10-Q · filed 2012-08-03 | $737.00K derived: sum of 3 quarters · filed 2013-02-26 | $1.10M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-03-31 | $817.00K 10-Q · filed 2012-05-09 | $365.00K derived: sum of 2 quarters · filed 2013-02-26 | $733.00K derived: sum of 3 quarters · filed 2013-02-26 | ||
| 2010-12-31 | -$452.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$84.00K derived: sum of 2 quarters · filed 2013-02-26 | -$997.00K 10-K · filed 2013-02-26 | ||
| 2010-09-30 | $368.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$545.00K 10-Q · filed 2011-11-07 | |||
| 2010-06-30 | -$913.00K 10-Q · filed 2011-08-05 | ||||
| 2009-12-31 | -$577.00K 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |